

Luis Masana MarÃ- n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2772743/publications.pdf>

Version: 2024-02-01

272
papers

20,584
citations

38660

50
h-index

11288

136
g-index

305
all docs

305
docs citations

305
times ranked

20071
citing authors

#	ARTICLE	IF	CITATIONS
1	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From ADA VINCI. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 941-953.	1.3	6
2	Pregnancy homocysteine and cobalamin status predict childhood metabolic health in the offspring. <i>Pediatric Research</i> , 2023, 93, 633-642.	1.1	3
3	Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 157-164.	1.4	64
4	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2022, 43, 830-833.	1.0	92
5	Perfil lipoproteico determinado por resonancia magnética. El momento de su utilización clínica ha llegado. <i>Revista Espanola De Cardiología</i> , 2022, 75, 5-8.	0.6	2
6	Situación en 2020 de los requerimientos para la utilización de inhibidores de PCSK9 en España: resultados de una encuesta nacional. <i>Clínica E Investigación En Arteriosclerosis</i> , 2022, 34, 10-18.	0.4	4
7	<scp>HTE</scp> 3.0: Knowledge-based systems in cascade for familial hypercholesterolemia detection and dyslipidemia treatment. <i>Expert Systems</i> , 2022, 39, e12835.	2.9	2
8	Long-term exposure to PM10 above WHO guidelines exacerbates COVID-19 severity and mortality. <i>Environment International</i> , 2022, 158, 106930.	4.8	32
9	Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol. <i>Diabetes Care</i> , 2022, 45, 232-240.	4.3	10
10	Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 197.	1.4	12
11	Estándares SEA 2022 para el control global del riesgo cardiovascular. <i>Clínica E Investigación En Arteriosclerosis</i> , 2022, 34, 130-179.	0.4	11
12	DNA methylation pattern of hypertriglyceridemic subjects. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2022, 34, 27-27.	0.1	0
13	Patrón de metilación en ADN de sujetos hipertriglicéridémicos. <i>Clínica E Investigación En Arteriosclerosis</i> , 2022, 34, 27-32.	0.4	2
14	Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2022, 34, 10-18.	0.1	0
15	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. <i>Advances in Therapy</i> , 2022, 39, 1857-1870.	1.3	7
16	The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study. <i>International Journal of Cardiology</i> , 2022, 361, 116-123.	0.8	24
17	Analysis of LDL and HDL size and number by nuclear magnetic resonance in a healthy working population: The LipoLab Study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13610.	0.8	8
18	Dietary intake and lipid levels in Norwegian and Spanish children with familial hypercholesterolemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1299-1307.	1.1	14

#	ARTICLE	IF	CITATIONS
19	El rastreo masivo de datos es una segunda oportunidad para mejorar el manejo de los pacientes fenotipo de hipercolesterolemia familiar. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2021, 33, 138-147.	0.4	1
20	Low HDL and high triglycerides predict COVID-19 severity. <i>Scientific Reports</i> , 2021, 11, 7217.	1.6	122
21	Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. <i>Heart</i> , 2021, 107, 1369-1375.	1.2	53
22	Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2021, 33, 138-147.	0.1	2
23	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.4	83
24	Metabolismo de los triglic�ridos y clasificaci�n de las hipertrigliceridemias. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2021, 33, 1-6.	0.4	3
25	�cido bempedoico. Mecanismo de acci�n y propiedades farmacocin�ticas y farmacodin�micas. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2021, 33, 53-57.	0.4	4
26	Plasma expression of microRNA-425-5p and microRNA-451a as biomarkers of cardiovascular disease in rheumatoid arthritis patients. <i>Scientific Reports</i> , 2021, 11, 15670.	1.6	12
27	Serum glycoproteins A and B assessed by 1H-NMR in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 330, 1-7.	0.4	9
28	Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 4281.	1.7	5
29	Evolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllers. <i>Frontiers in Immunology</i> , 2021, 12, 730691.	2.2	2
30	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1279-1289.	0.8	369
31	Magnetic resonance-assessed lipoprotein profile. The time has come for its clinical use. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 75, 5-5.	0.4	0
32	MCF-7 Drug Resistant Cell Lines Switch Their Lipid Metabolism to Triple Negative Breast Cancer Signature. <i>Cancers</i> , 2021, 13, 5871.	1.7	4
33	Statistical mediation of the relationships between chronological age and lipoproteins by nonessential amino acids in healthy men. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 6169-6178.	1.9	1
34	Glycoprotein Profile Measured by a 1H-Nuclear Magnetic Resonance Based on Approach in Patients with Diabetes: A New Robust Method to Assess Inflammation. <i>Life</i> , 2021, 11, 1407.	1.1	7
35	Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 775677.	1.5	4
36	Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk. <i>Frontiers in Physiology</i> , 2021, 12, 781789.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype. <i>Atherosclerosis</i> , 2020, 292, 42-51.	0.4	9
38	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 325-332.	1.0	0
39	Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 161-167.	0.4	10
40	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach. <i>JAMA Cardiology</i> , 2020, 5, 1452.	3.0	2
41	Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU). <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 183-192.	0.1	0
42	Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®). <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 219-229.	0.1	6
43	Documento de consenso de un grupo de expertos de la Sociedad Española de Arteriosclerosis (SEA) sobre el uso clínico de la resonancia magnética nuclear en el estudio del metabolismo lipoproteico (Liposcale). <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 32, 219-229.	0.4	9
44	Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms. <i>Biomolecules</i> , 2020, 10, 1275.	1.8	9
45	Glycoprotein Profile Assessed by 1H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1344.	1.0	14
46	Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 348-353.	0.4	2
47	Plasma glucose, triglycerides, VLDL, leptin and resistin levels as potential biomarkers for myocardial fat in mice. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 8-14.	0.1	1
48	LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis. <i>Circulation Research</i> , 2020, 127, 778-792.	2.0	45
49	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets. <i>Current Cardiology Reports</i> , 2020, 22, 66.	1.3	26
50	Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 49-58.	0.1	0
51	Niveles plasmáticos de glucosa, triglicéridos, VLDL, leptina y resistina como potenciales biomarcadores de la grasa miocárdica en ratones. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 32, 8-14.	0.4	4
52	Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry. <i>Atherosclerosis</i> , 2020, 299, 24-31.	0.4	20
53	Perfil clínico de los pacientes tratados con evolocumab en unidades de lípidos/medicina interna en España. Estudio observacional (RETOSS-IMU). <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 32, 183-192.	0.4	4
54	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020, 42, e30-e34.	1.2	6

#	ARTICLE	IF	CITATIONS
55	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020, 42, e49-e58.	1.2	23
56	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	1.0	776
57	Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 32, 49-58.	0.4	3
58	Treating dyslipidemia: something more than giving statins. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 119-120.	0.1	0
59	Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1080.	1.0	33
60	HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3151.	1.8	58
61	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 128-139.	0.1	6
62	EstÁndares SEA 2019 para el control global del riesgo cardiovascular. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 1-43.	0.4	8
63	The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario. <i>Journal of Clinical Medicine</i> , 2019, 8, 1793.	1.0	40
64	Update of therapeutic planning tables oriented towards obtaining therapeutic objectives. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 271-277.	0.1	3
65	Indicaciones de los inhibidores de PCSK9 en la prÁctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 128-139.	0.4	28
66	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. <i>Atherosclerosis</i> , 2019, 287, 89-92.	0.4	29
67	Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. <i>Advances in Therapy</i> , 2019, 36, 1786-1811.	1.3	35
68	Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 12-21.	1.5	35
69	Assessment of arterial stiffness variables in patients with rheumatoid arthritis: A mediation analysis. <i>Scientific Reports</i> , 2019, 9, 4543.	1.6	15
70	Palmitate decreases migration and proliferation and increases oxidative stress and inflammation in smooth muscle cells: role of the Nrf2 signaling pathway. <i>American Journal of Physiology - Cell Physiology</i> , 2019, 316, C888-C897.	2.1	13
71	Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives. <i>Journal of Medical Genetics</i> , 2019, 56, 711-717.	1.5	10
72	Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 519-520.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Estimaci3n del porcentaje de pacientes con enfermedad coronaria estable candidatos a recibir inhibidores de PCSK9. Respuesta. Revista Espanola De Cardiologia, 2019, 72, 519-520.	0.6	3
74	Low-density lipoprotein net charge is a risk factor for atherosclerosis in lupus patients independent of lipid concentrations. International Journal of Rheumatic Diseases, 2019, 22, 480-487.	0.9	7
75	Extracellular FABP4 uptake by endothelial cells is dependent on cytokeratin 1 expression. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 234-244.	1.2	13
76	Actualizaci3n de las tablas de planificaci3n terap3utica hipocolesterolemiante orientadas a la obtenci3n de los objetivos terap3uticos. Cl3nica E Investigaci3n En Arteriosclerosis, 2019, 31, 271-277.	0.4	13
77	Tratar la dislipemia, algo m3s que dar estatinas. Cl3nica E Investigaci3n En Arteriosclerosis, 2019, 31, 119-120.	0.4	1
78	MicroRNA differential expression shared between rheumatoid arthritis and acute myocardial infarction: an exploratory study. Clinical and Experimental Rheumatology, 2019, 37, 886-887.	0.4	2
79	Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. Journal of Nutrition, 2018, 148, 285-297.	1.3	13
80	Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in Lipid and Vascular Risk Units. EROMOT study. Cl3nica E Investigaci3n En Arteriosclerosis (English Edition), 2018, 30, 1-9.	0.1	4
81	Valor de los par3metros lip3dicos y apoproteicos para la detecci3n de hipercolesterolemia familiar en la infancia. Proyecto DECOPIN. Cl3nica E Investigaci3n En Arteriosclerosis, 2018, 30, 170-178.	0.4	9
82	Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients. Revista Espanola De Cardiologia (English Ed), 2018, 71, 1010-1017.	0.4	10
83	Altered HDL Remodeling and Functionality in Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2018, 71, 466-468.	1.2	13
84	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels - The zero-LDL hypothesis. Journal of Clinical Lipidology, 2018, 12, 292-299.e3.	0.6	51
85	Autosomal Recessive Hypercholesterolemia. Journal of the American College of Cardiology, 2018, 71, 279-288.	1.2	38
86	Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia. Atherosclerosis, 2018, 270, 117-122.	0.4	11
87	N3mero de pacientes candidatos a recibir inhibidores de la PCSK9 seg3n datos de 2,5 millones de participantes de la pr3ctica cl3nica real. Revista Espanola De Cardiologia, 2018, 71, 1010-1017.	0.6	23
88	FABP4 inhibitor BMS309403 decreases saturated-fatty-acid-induced endoplasmic reticulum stress-associated inflammation in skeletal muscle by reducing p38 MAPK activation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 604-613.	1.2	33
89	The Zero-LDL Hypothesis. Towards Extremely Low LDL Concentrations. Revista Espanola De Cardiologia (English Ed), 2018, 71, 591-592.	0.4	1
90	Causas de no consecuci3n del objetivo terap3utico del colesterol de las lipoprote3nas de baja densidad en pacientes de alto y muy alto riesgo vascular controlados en Unidades de L3pidos y Riesgo Vascular. Estudio EROMOT. Cl3nica E Investigaci3n En Arteriosclerosis, 2018, 30, 1-9.	0.4	8

#	ARTICLE	IF	CITATIONS
91	Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. <i>Journal of Clinical Lipidology</i> , 2018, 12, 211-218.	0.6	14
92	Autosomal recessive hypercholesterolemia in Spain. <i>Atherosclerosis</i> , 2018, 269, 1-5.	0.4	18
93	Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1452-1462.	0.6	14
94	Detecting familial hypercholesterolemia earlier in life by actively searching for affected children: The DECOPIN project. <i>Atherosclerosis</i> , 2018, 278, 210-216.	0.4	18
95	Characterization of ¹ H NMR Plasma Glycoproteins as a New Strategy To Identify Inflammatory Patterns in Rheumatoid Arthritis. <i>Journal of Proteome Research</i> , 2018, 17, 3730-3739.	1.8	46
96	Lipid and lipoprotein parameters for detection of familial hypercholesterolemia in childhood. The DECOPIN Project. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2018, 30, 170-178.	0.1	1
97	Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1482-1492.e3.	0.6	22
98	Variables associated with subclinical atherosclerosis in a cohort of rheumatoid arthritis patients: Sex-specific associations and differential effects of disease activity and age. <i>PLoS ONE</i> , 2018, 13, e0193690.	1.1	12
99	Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins. <i>Molecular Carcinogenesis</i> , 2017, 56, 208-217.	1.3	89
100	Is there a role for lifestyle changes in cardiovascular prevention? What, when and how?. <i>Atherosclerosis Supplements</i> , 2017, 26, 2-15.	1.2	31
101	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	1.0	2,292
102	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. <i>Atherosclerosis</i> , 2017, 262, 107-112.	0.4	22
103	Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. <i>Journal of Endocrinology</i> , 2017, 233, R173-R184.	1.2	86
104	Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1013-1022.	0.6	61
105	Familial hypercholesterolemia in childhood and adolescents: A hidden reality. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017, 29, 129-140.	0.1	2
106	Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. <i>Clinical Therapeutics</i> , 2017, 39, 771-786.e3.	1.1	45
107	Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 687-693.	4.3	45
108	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1448-1457.	0.6	48

#	ARTICLE	IF	CITATIONS
109	Lipoprotein particle number and size distribution in apparently healthy spanish population according to sex and age, assessed by nuclear magnetic resonance. <i>Atherosclerosis</i> , 2017, 263, e86.	0.4	0
110	New perspectives on CKD-induced dyslipidemia. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 967-976.	1.5	31
111	Hipercolesterolemia familiar en la infancia y la adolescencia: una realidad oculta. <i>Cl�nica E Investigaci3n En Arteriosclerosis</i> , 2017, 29, 129-140.	0.4	8
112	Caveolin 3 deficiency myopathy associated with dyslipidemia: Treatment challenges and possible pathophysiological association. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1280-1283.	0.6	6
113	Results of the REVEAL study. Why should we not welcome a new lipid-lowering agent?. <i>Cl�nica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2017, 29, 278-279.	0.1	0
114	Adipose-Derived Fatty Acid-Binding Proteins Plasma Concentrations Are Increased in Breast Cancer Patients. <i>Oncologist</i> , 2017, 22, 1309-1315.	1.9	29
115	Resultados del estudio REVEAL. �Por qu� no debemos dar la bienvenida a un nuevo agente hipolipemiante?. <i>Cl�nica E Investigaci3n En Arteriosclerosis</i> , 2017, 29, 278-279.	0.4	0
116	Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: �Herniated� HDL, a common feature in diabetes. <i>Scientific Reports</i> , 2016, 6, 19249.	1.6	25
117	Maximum Low-density Lipoprotein Cholesterol Lowering Capacity Achievable With Drug Combinations. When 50 Plus 20 Equals 60. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 342-343.	0.4	7
118	M�xima reducci3n de colesterol unido a lipoprote�nas de baja densidad alcanzable con combinaciones farmacol3gicas. Cuando 50 m�s 20 suma 60. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 342-343.	0.6	24
119	Exogenous FABP4 induces endoplasmic reticulum stress in HepG2 liver cells. <i>Atherosclerosis</i> , 2016, 249, 191-199.	0.4	34
120	Long-term effects of continuous positive airway pressure treatment on subclinical atherosclerosis in obstructive sleep apnoea syndrome. <i>Medicina Cl�nica (English Edition)</i> , 2016, 147, 1-6.	0.1	3
121	Intraabdominal fat redistribution in long-term continuous positive airway pressure treatment in obstructive sleep apnea patients. <i>Medicina Cl�nica (English Edition)</i> , 2016, 146, 484-487.	0.1	1
122	APOA5 genetic and epigenetic variability jointly regulate circulating triacylglycerol levels. <i>Clinical Science</i> , 2016, 130, 2053-2059.	1.8	15
123	Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. <i>Cardiovascular Diabetology</i> , 2016, 15, 107.	2.7	28
124	Dose wisely! How lipid-lowering undertreatment can lead to overtreatment. <i>Atherosclerosis</i> , 2016, 255, 126-127.	0.4	3
125	Impact of epidermal fatty acid binding protein on 2D-NMR�assessed atherogenic dyslipidemia and related disorders. <i>Journal of Clinical Lipidology</i> , 2016, 10, 330-338.e2.	0.6	9
126	Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. <i>Cl�nica E Investigaci3n En Arteriosclerosis</i> , 2016, 28, 71-78.	0.4	35

#	ARTICLE	IF	CITATIONS
127	Letter to Editor: Increased Presence of Remnant Lipoprotein Cholesterol in The Hdl of Diabetic Subjects. <i>Annals of Clinical and Laboratory Science</i> , 2016, 46, 229-32.	0.2	0
128	Simvastatin Increases Fibulin-2 Expression in Human Coronary Artery Smooth Muscle Cells via RhoA/Rho-Kinase Signaling Pathway Inhibition. <i>PLoS ONE</i> , 2015, 10, e0133875.	1.1	15
129	AICAR Protects against High Palmitate/High Insulin-Induced Intramyocellular Lipid Accumulation and Insulin Resistance in HL-1 Cardiac Cells by Inducing PPAR-Target Gene Expression. <i>PPAR Research</i> , 2015, 2015, 1-12.	1.1	12
130	Body mass index correlates with atherogenic lipoprotein profile even in nonobese, normoglycemic, and normolipidemic healthy men. <i>Journal of Clinical Lipidology</i> , 2015, 9, 824-831.e1.	0.6	12
131	Is complying with the recommendations of sodium intake beneficial for health in individuals at high cardiovascular risk? Findings from the PREDIMED study. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 440-448.	2.2	25
132	The pleiotropic role of HDL in autoimmune diseases. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2015, 27, 97-106.	0.4	10
133	Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. <i>Clinical Science</i> , 2015, 128, 877-882.	1.8	25
134	Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. <i>Journal of Lipid Research</i> , 2015, 56, 737-746.	2.0	133
135	IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"? <i>Atherosclerosis</i> , 2015, 240, 161-162.	0.4	64
136	APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. <i>Atherosclerosis</i> , 2015, 240, 98-104.	0.4	28
137	Design and evaluation of standard lipid prediction models based on 1H-NMR spectroscopy of human serum/plasma samples. <i>Metabolomics</i> , 2015, 11, 1394-1404.	1.4	3
138	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	1.0	644
139	In Vitro Biocompatibility of Surface-Modified Porous Alumina Particles for HepG2 Tumor Cells: Toward Early Diagnosis and Targeted Treatment. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 18600-18608.	4.0	23
140	New insights into circulating FABP4: Interaction with cytokeratin 1 on endothelial cell membranes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 2966-2974.	1.9	28
141	FABP4 plasma concentrations are determined by acquired metabolic derangements rather than genetic determinants. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 875-880.	1.1	9
142	Las Competencias Profesionales de Los Titulados en Medicina Mejoran Con la Introducci3n de un Programa de Simulaci3n Con Pacientes Estandarizados y MINIC-CEX. <i>Procedia, Social and Behavioral Sciences</i> , 2015, 196, 25-29.	0.5	1
143	Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. <i>Atherosclerosis</i> , 2015, 238, 213-219.	0.4	23
144	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. <i>European Journal of Human Genetics</i> , 2015, 23, 381-387.	1.4	15

#	ARTICLE	IF	CITATIONS
145	Estimating Cardiovascular Risk in Spain by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 417-425.	0.4	9
146	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	1.0	835
147	Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: The di@bet.es study. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2014, 26, 107-114.	0.4	15
148	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.4	419
149	Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2014, 26, 274-284.	0.4	16
150	Should We Forget About Low-Density Lipoprotein Cholesterol?. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1228-1229.	1.2	18
151	Low-carbohydrate, high-protein, high-fat diet alters small peripheral artery reactivity in metabolic syndrome patients. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2014, 26, 58-65.	0.4	5
152	Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate��high cardiovascular risk. <i>Journal of Nutritional Biochemistry</i> , 2014, 25, 642-646.	1.9	19
153	MTP gene polymorphisms and postprandial lipemia in familial combined hyperlipidemia: Effects of treatment with atorvastatin. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2014, 26, 49-57.	0.4	5
154	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 655-666.	5.5	473
155	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
156	Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients. <i>Cardiovascular Diabetology</i> , 2013, 12, 72.	2.7	19
157	Akt and ERK/Nrf2 activation by PUFA oxidation-derived aldehydes upregulates FABP4 expression in human macrophages. <i>Atherosclerosis</i> , 2013, 230, 216-222.	0.4	16
158	Pitavastatin in cardiometabolic disease: therapeutic profile. <i>Cardiovascular Diabetology</i> , 2013, 12, S2.	2.7	21
159	Human serum/plasma lipoprotein analysis by NMR: Application to the study of diabetic dyslipidemia. <i>Progress in Nuclear Magnetic Resonance Spectroscopy</i> , 2013, 70, 1-24.	3.9	55
160	Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy. <i>Atherosclerosis</i> , 2013, 226, 471-475.	0.4	17
161	HPS2-THRIVE results: Bad for niacin/laropirant, good for ezetimibe?. <i>Atherosclerosis</i> , 2013, 229, 449-450.	0.4	12
162	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	1.0	2,132

#	ARTICLE	IF	CITATIONS
163	Even low physical activity levels improve vascular function in overweight and obese postmenopausal women. <i>Menopause</i> , 2013, 20, 1036-1042.	0.8	13
164	Negative effect of a low-carbohydrate, high-protein, high-fat diet on small peripheral artery reactivity in patients with increased cardiovascular risk. <i>British Journal of Nutrition</i> , 2013, 109, 1241-1247.	1.2	13
165	FABP4 Induces Vascular Smooth Muscle Cell Proliferation and Migration through a MAPK-Dependent Pathway. <i>PLoS ONE</i> , 2013, 8, e81914.	1.1	51
166	Circulating FABP4 and FABP5 Levels Are Differently Linked to OSA Severity and Treatment. <i>Sleep</i> , 2013, 36, 1831-1837.	0.6	14
167	La adición de leche fermentada suplementada con esteroles vegetales mejora el cumplimiento de los cambios en el estilo de vida en los pacientes hipercolesterolémicos. <i>Estudio RECIFE. Clínica E Investigaci3n En Arteriosclerosis</i> , 2012, 24, 173-180.	0.4	0
168	FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study. <i>Atherosclerosis</i> , 2012, 222, 229-234.	0.4	28
169	Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. <i>Atherosclerosis</i> , 2012, 222, 449-455.	0.4	61
170	Lifestyle Changes Lower FABP4 Plasma Concentration in Patients With Cardiovascular Risk. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 152-157.	0.4	3
171	Cambios de estilo de vida disminuyen las concentraciones plasmáticas de FABP4 en pacientes con riesgo cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 152-157.	0.6	13
172	Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. <i>Cardiovascular Diabetology</i> , 2012, 11, 72.	2.7	62
173	Two Variants in the Fibulin2 Gene Are Associated with Lower Systolic Blood Pressure and Decreased Risk of Hypertension. <i>PLoS ONE</i> , 2012, 7, e43051.	1.1	9
174	Small artery dilation and endothelial markers in cardiovascular risk patients. <i>European Journal of Clinical Investigation</i> , 2012, 42, 34-41.	1.7	10
175	Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 2407-2415.	1.9	27
176	Cocoa, Hazelnuts, Sterols and Soluble Fiber Cream Reduces Lipids and Inflammation Biomarkers in Hypertensive Patients: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2012, 7, e31103.	1.1	37
177	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	1.0	993
178	Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess. <i>Gynecological Endocrinology</i> , 2011, 27, 935-939.	0.7	12
179	Análisis funcional de mutaciones en el promotor del LDLR y su relación con la hipercolesterolemia familiar. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2011, 23, 119-124.	0.4	1
180	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	1.0	2,767

#	ARTICLE	IF	CITATIONS
181	High-density lipoprotein cholesterol and apolipoprotein A1 levels strongly influence the reactivity of small peripheral arteries. <i>Atherosclerosis</i> , 2011, 216, 115-119.	0.4	27
182	Heterozygous Familial Hypercholesterolaemic Patients have Increased Arterial Stiffness, as Determined using the Augmentation Index. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 1110-1116.	0.9	18
183	Surface fitting of 2D diffusion-edited 1H NMR spectroscopy data for the characterisation of human plasma lipoproteins. <i>Metabolomics</i> , 2011, 7, 572-582.	1.4	25
184	Functional analysis of LDLR promoter and 5' UTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia. <i>Human Mutation</i> , 2011, 32, 868-872.	1.1	26
185	Effect of the long-term regular intake of virgin olive oil on the phenolic metabolites in human fasting plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 53, 68-74.	1.4	8
186	Effect of nut consumption on oxidative stress and the endothelial function in metabolic syndrome. <i>Clinical Nutrition</i> , 2010, 29, 373-380.	2.3	85
187	Polyunsaturated fatty acids down-regulate in vitro expression of the key intestinal cholesterol absorption protein NPC1L1: no effect of monounsaturated nor saturated fatty acids. <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 518-525.	1.9	56
188	Nuclear Magnetic Resonance Lipoprotein Subclasses and the APOE Genotype Influence Carotid Atherosclerosis in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 2259-2267.	1.0	20
189	FABP4 plasma levels are increased in familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 2010, 51, 1173-1178.	2.0	11
190	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	1.0	1,392
191	Pitavastatin "from clinical trials to clinical practice. <i>Atherosclerosis Supplements</i> , 2010, 11, 15-22.	1.2	19
192	APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. <i>Atherosclerosis</i> , 2010, 209, 201-205.	0.4	38
193	Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2010, 213, 329-331.	0.4	55
194	Cocientes lipoproteicos: significado fisiológico y utilidad clínica de los Índices aterogénicos en prevención cardiovascular. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2010, 22, 25-32.	0.4	14
195	FABP4 plasma levels are increased in familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 2010, 51, 1173-1178.	2.0	26
196	Sonographic evaluation of Achilles tendons and carotid atherosclerosis in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2009, 204, 345-347.	0.4	20
197	Prox-1 and FOXC2 gene expression in adipose tissue: A potential contributory role of the lymphatic system to familial combined hyperlipidaemia. <i>Atherosclerosis</i> , 2009, 206, 343-345.	0.4	21
198	Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. <i>Vascular Health and Risk Management</i> , 2009, 5, 757-65.	1.0	421

#	ARTICLE	IF	CITATIONS
199	Plant sterol-enriched fermented milk enhances the attainment of LDL-cholesterol goal in hypercholesterolemic subjects. <i>European Journal of Nutrition</i> , 2008, 47, 32-39.	1.8	69
200	Gene expression analysis of a human enterocyte cell line reveals downregulation of cholesterol biosynthesis in response to short-chain fatty acids. <i>IUBMB Life</i> , 2008, 60, 757-764.	1.5	98
201	Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2008, 102, 1187-1193.e1.	0.7	153
202	Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: A 12-week, multicenter, randomized, open-label, parallel-group study. <i>Clinical Therapeutics</i> , 2008, 30, 84-97.	1.1	18
203	Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 380-387.	1.1	45
204	The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. <i>Atherosclerosis</i> , 2008, 199, 147-153.	0.4	32
205	Intermediate levels of paraoxonase-1 activity are associated to lower intima-media thickness in HIV-infected patients. <i>Atherosclerosis</i> , 2008, 199, 232.	0.4	0
206	El gen de la apolipoproteína A5 se expresa en el intestino humano. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2008, 20, 129-134.	0.4	1
207	Los 3cidos grasos poliinsaturados disminuyen la expresi3n in vitro de la prote3na NPC1L1, clave en la absorci3n intestinal de colesterol. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2008, 20, 200-206.	0.4	0
208	The apolipoprotein A5 gene 1131T>C polymorphism affects vitamin E plasma concentrations in type 2 diabetic patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 453-7.	1.4	16
209	Plasma Fatty Acid-Binding Protein 4 Increases with Renal Dysfunction in Type 2 Diabetic Patients without Microalbuminuria. <i>Clinical Chemistry</i> , 2008, 54, 181-187.	1.5	49
210	Retinoic acid induces PGI synthase expression in human endothelial cells. <i>Journal of Lipid Research</i> , 2008, 49, 1707-1714.	2.0	21
211	Influence of Inflammatory Variables on Intima-Media Thickness. <i>Stroke</i> , 2008, 39, e16.	1.0	0
212	Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. <i>Journal of Lipid Research</i> , 2008, 49, 1746-1751.	2.0	80
213	Tumor necrosis factor-alpha -1031 T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1697-703.	1.0	24
214	Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (CRABP2) with increased circulating low-density lipoprotein cholesterol. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 615-20.	1.4	10
215	Carotid intima-media thickness course in HIV-infected patients: beyond classical cardiovascular risk factors. <i>Aids</i> , 2007, 21, 1989-1990.	1.0	2
216	Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene 1131T>C variant and associations with plasma lipids and lipid peroxidation. <i>Journal of Lipid Research</i> , 2007, 48, 2506-2513.	2.0	20

#	ARTICLE	IF	CITATIONS
217	Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 829-34.	1.4	3
218	Effects of soluble fiber (Plantago ovatahusk) on plasma lipids, lipoproteins, and apolipoproteins in men with ischemic heart disease. <i>American Journal of Clinical Nutrition</i> , 2007, 85, 1157-1163.	2.2	50
219	Autosomal recessive hypercholesterolemia in Spanish kindred due to a large deletion in the ARH gene. <i>Molecular Genetics and Metabolism</i> , 2007, 92, 243-248.	0.5	20
220	Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. <i>Atherosclerosis</i> , 2007, 194, 175-181.	0.4	62
221	Efecto del Ácido 13-cis-retinoico sobre el perfil de expresi3n g3nica de c3lulas HUVEC (human umbilical) Tj ETQq1 1 0.784314 0.4 0	0.4	0
222	The Role of Immunity and Inflammation in the Progression of Atherosclerosis in Patients With HIV Infection. <i>Stroke</i> , 2007, 38, 2477-2484.	1.0	72
223	Management of Dyslipidemia in the Metabolic Syndrome. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 39-58.	1.0	54
224	HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: The role of monocyte chemoattractant protein-1. <i>Cytokine</i> , 2006, 34, 51-55.	1.4	46
225	Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. <i>Aids</i> , 2006, 20, 1675-1677.	1.0	54
226	Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA51131T1C Gene Variation. <i>Clinical Chemistry</i> , 2006, 52, 1914-1919.	1.5	48
227	The stromal derived factor-1 mutated allele (SDF1-3A) is associated with a lower incidence of atherosclerosis in HIV-infected patients. <i>Aids</i> , 2005, 19, 1877-1883.	1.0	20
228	Additive Effects of the PPAR3, APOE, and FABP-2 Genes in Increasing Daylong Triglycerides of Normolipidemic Women to Concentrations Comparable to Those in Men. <i>Clinical Chemistry</i> , 2005, 51, 864-871.	1.5	15
229	Long-term safety and, tolerability profiles andlipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: A multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. <i>Clinical Therapeutics</i> , 2005, 27, 174-184.	1.1	60
230	The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. <i>Aids</i> , 2005, 19, 341-2.	1.0	28
231	Generation of eight adjacent mutations in a single step using a site-directed mutagenesis kit. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 384-6.	1.4	6
232	Atherosclerosis in Patients Infected With HIV Is Influenced by a Mutant Monocyte Chemoattractant Protein-1 Allele. <i>Circulation</i> , 2004, 110, 2204-2209.	1.6	121
233	Evidence of hypolipemiant and antioxidant properties of argan oil derived from the argan tree (<i>Argania spinosa</i>)*1. <i>Clinical Nutrition</i> , 2004, 23, 1159-1166.	2.3	116
234	Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate. <i>European Journal of Pharmacology</i> , 2004, 496, 205-212.	1.7	5

#	ARTICLE	IF	CITATIONS
235	Aldehydes mediate tissue factor induction: A possible mechanism linking lipid peroxidation to thrombotic events. <i>Journal of Cellular Physiology</i> , 2004, 198, 230-236.	2.0	11
236	Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. <i>Current Medical Research and Opinion</i> , 2004, 20, 1437-1445.	0.9	85
237	Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. <i>Aids</i> , 2004, 18, 819-821.	1.0	46
238	Familial hypercholesterolemia in Morocco: first report of mutations in the LDL receptor gene. <i>Journal of Human Genetics</i> , 2003, 48, 199-203.	1.1	27
239	Prevalence of and predictors of bicuspid aortic valves in patients with dilated aortic roots. <i>American Journal of Cardiology</i> , 2003, 91, 619-622.	0.7	35
240	Cytotoxic effects of the lipid peroxidation product 2,4-decadienal in vascular smooth muscle cells. <i>Atherosclerosis</i> , 2003, 169, 245-250.	0.4	24
241	Two novel single nucleotide polymorphisms in the promoter of the Cellular Retinoic Acid Binding Protein II gene (CRABP-II). <i>Molecular and Cellular Probes</i> , 2003, 17, 21-23.	0.9	10
242	HDL derived from the different phases of conjugated diene formation reduces membrane fluidity and contributes to a decrease in free cholesterol efflux from human THP-1 macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2003, 1633, 143-148.	1.2	25
243	The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 517-21.	1.4	33
244	Short-term Efficacy and Safety of Extended-release Fluvastatin in a Large Cohort of Elderly Patients. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 225-231.	0.7	33
245	Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2003, 6, 177-187.	1.3	51
246	High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy. <i>Aids</i> , 2003, 17, 1173-1178.	1.0	35
247	Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. <i>Aids</i> , 2002, 16, 1383-1389.	1.0	92
248	Unsaturated fatty acids and their oxidation products stimulate CD36 gene expression in human macrophages. <i>Atherosclerosis</i> , 2002, 164, 45-56.	0.4	63
249	Low-density lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets. <i>Atherosclerosis</i> , 2001, 155, 99-112.	0.4	18
250	Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility Commentary: Early discontinuation violates Helsinki principles. <i>BMJ: British Medical Journal</i> , 2001, 322, 603-606.	2.4	93
251	Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: Possible contribution of phospholipase A2 to this atherogenic profile. <i>Arthritis and Rheumatism</i> , 2001, 44, 2761-2767.	6.7	125
252	Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 721-30.	1.4	70

#	ARTICLE	IF	CITATIONS
253	Platelet function in patients with familial hypertriglyceridemia: Evidence that platelet reactivity is modulated by apolipoprotein E content of very low-density lipoprotein particles. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 942-949.	1.5	30
254	Molecular Requirements in the Recognition of Low-Density Lipoproteins (LDL) by Specific Platelet Membrane Receptors. <i>Thrombosis Research</i> , 2000, 99, 51-60.	0.8	5
255	Intestinal fatty acid binding protein polymorphism at codon 54 is not associated with postprandial responses to fat and glucose tolerance tests in healthy young Europeans. Results from EARS II participants. <i>Atherosclerosis</i> , 2000, 152, 317-325.	0.4	51
256	Hepatic production of apolar aldehydes in rats with carbon tetrachloride-induced cirrhosis. <i>Molecular and Cellular Biochemistry</i> , 1999, 198, 57-60.	1.4	10
257	Mechanisms for Regulating Platelet High Density Lipoprotein Type3 Binding Sites. <i>Thrombosis Research</i> , 1999, 94, 33-44.	0.8	13
258	A Comparison of Lifestyle, Genetic, Bioclinical and Biochemical Variables of Offspring with and without Family Histories of Premature Coronary Heart Disease: The Experience of the European Atherosclerosis Research Studies. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1999, 6, 183-188.	3.1	15
259	Vitamin A is linked to the expression of the AI-CIII-AIV gene cluster in familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 1999, 40, 426-431.	2.0	9
260	Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction. <i>Atherosclerosis</i> , 1998, 140, 155-159.	0.4	37
261	Effect of malabsorption on nutritional status and resting energy expenditure in HIV-infected patients. <i>Aids</i> , 1998, 12, 1965-1972.	1.0	18
262	Oleic Acid Rich Diet Protects Against the Oxidative Modification of High Density Lipoprotein. <i>Free Radical Biology and Medicine</i> , 1997, 22, 1037-1045.	1.3	69
263	Oxidized Lipoproteins Including HDL and Their Lipid Peroxidation Products Inhibit TNF- α Secretion by THP-1 Human Macrophages. <i>Free Radical Biology and Medicine</i> , 1997, 23, 658-667.	1.3	32
264	Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts. <i>Cardiovascular Drugs and Therapy</i> , 1997, 11, 653-658.	1.3	7
265	Prevalence of Dementia in a Semi-Rural Population of Catalunya, Spain. <i>Neuroepidemiology</i> , 1996, 15, 33-41.	1.1	34
266	Plasma lipoprotein alterations in patients with chronic hepatocellular liver disease resulting from alcohol abuse: effects of alcohol intake cessation. <i>Journal of Hepatology</i> , 1994, 21, 704-709.	1.8	10
267	In vitro oxidised HDL is recognised by the scavenger receptor of macrophages: implications for its protective role in vivo. <i>Atherosclerosis</i> , 1994, 105, 179-189.	0.4	44
268	Low-density lipoprotein metabolism in rats treated with cyclosporine. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 678-683.	1.5	34
269	Relationship between hepatic lipid peroxidation and fibrogenesis in carbon tetrachloride-treated rats: effect of zinc administration. <i>Clinical Science</i> , 1992, 83, 695-700.	1.8	72
270	Interaction of oxidized low density lipoproteins with both apo B,E and scavenger receptors. A model for its production in vitro. <i>Clinica Chimica Acta</i> , 1992, 210, 93-108.	0.5	1

#	ARTICLE	IF	CITATIONS
271	Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. American Journal of Cardiology, 1991, 68, 863-867.	0.7	18
272	Abnormalities of Lipoprotein Metabolism in Patients with the Nephrotic Syndrome. New England Journal of Medicine, 1990, 323, 579-584.	13.9	275